Bluejay Diagnostics released baseline data from its SYMON-II study, evaluating the IL-6 biomarker for mortality risk in sepsis patients.
The Lovell Government Services agreement establishes federal procurement infrastructure for the Symphony platform, but commercialization remains dependent on regulatory authorization. Key Investor TakeawaysBluejay Diagnostics (NASDAQ:BJDX) has formed a distribution, co-marketing and strategic partnership with Lovell Government Services targeting U.
Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare ChannelsACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and Lovell Government Services, Inc. (“Lovell”), a Service-Disabled Veteran-Owned Co
This is the newest page. Registered accounts read further back.